Skip to main content
. 2020 Mar 17;7(3):e708. doi: 10.1212/NXI.0000000000000708

Figure 1. Comparison of serum biomarkers in patients with MOGAD and NMOSD with AQP4-Ab.

Figure 1

(A and B) Serum NfL levels, (C and D) serum GFAP levels, and (E and F) serum tau levels were compared between patients with MOGAD and NMOSD with AQP4-Abs. In panels A, C, and E, all samples from each group were included. In panels B, D, and F, each group was subdivided into relapse and remission states. The line in the center represents the median. The whiskers indicate the interquartile range. The p values were obtained via analysis of covariance, adjusted for age and Expanded Disability Status Scale score. *p < 0.05. AQP4-Abs = anti-aquaporin-4 antibodies; GFAP = glial fibrillary acidic protein; MOGAD = myelin oligodendrocyte glycoprotein antibody–associated disease; NfL = neurofilament light chain; NMOSD = neuromyelitis optica spectrum disorder.